[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertisement
Advertise Here
August 22, 2011
Volume 89, Number 34
p. 10

Pfizer Wards Off Viagra Challenge

Pharmaceuticals: Ruling protects exclusivity for blockbuster drug until 2019

Rick Mullin

  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Viagra Shutterstock

A federal judge in Virginia has ruled in favor of Pfizer in the pharmaceutical giant’s Viagra patent infringement case against generics maker Teva Pharmaceutical Industries. The decision secures Pfizer’s U.S. patent exclusivity on the blockbuster erectile dysfunction treatment for eight more years.

Pfizer’s original patent on sildenafil citrate, Viagra’s active ingredient, is due to expire next year. Teva argued that a second patent, on the use of sildenafil citrate specifically to treat erectile dysfunction, is unenforceable. The court upheld the second Pfizer patent, however, which doesn’t expire until 2019.

The decision, by Judge Rebecca Beach Smith, provides a modicum of relief for Pfizer, which faces imminent loss of patent protection for its cholesterol-lowering medicine Lipitor, the top-selling drug in the world. Viagra sales reached $1.9 billion in 2010, about half of which are U.S. sales, compared with total sales of $10.7 billion for Lipitor.

“We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction,” says Amy W. Schulman, Pfizer’s general counsel.

Viagra is the first commercialized therapy in a category of drugs that now includes Eli Lilly & Co.’s Cialis and Bayer’s Levitra. It was discovered serendipitously during clinical trials of sildenafil citrate as a chest pain treatment. The drug performed poorly for that indication, but men participating in the trial reported experiencing spontaneous erections.

The court’s decision, which remains subject to appeal, prevents Teva from receiving approval for a generic form of Viagra until October 2019. Pfizer acknowledges other patent challenges to Viagra, although no trials in those cases have been scheduled.

The decision surprised some observers, says Damien Conover, a stock analyst with Morningstar. “I think most people expected the patent exclusivity for Viagra to run out next year in most major markets,” he says.

“Pfizer is not completely out of the woods yet,” Conover adds, pointing to other pending challenges to the Viagra patent. “But Teva is a nice barometer for what will likely happen in those cases.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!